FDA GUIDANCE · FINALJune 26, 2025

Early Lyme Disease as Manifested by Erythema Migrans: Developing Drugs for Treatment

What this record is not

Guidance details are published by the U.S. FDA; SPEQ surfaces them for reference and is not affiliated with or endorsed by the FDA. The authoritative text is on fda.gov.

Status

Final

Topic

Pediatric Product Development, Clinical - Antimicrobial

Issue date

June 26, 2025

CHECKING ACCESS

Checking your access…

READ THE FULL GUIDANCE

The complete guidance document — every recommendation and its scope — is published by the FDA. SPEQ surfaces and indexes it for reference; the authoritative text lives on fda.gov.

View on fda.gov →

PUT THIS GUIDANCE TO WORK

Decode the standardsThe requirements this guidance interprets →Assess your quality systemBaseline against 12 GxP domains in 10 minutes →All FDA guidanceBrowse the live guidance feed →